Overview

Mesotherapy Treatment of Irritable Bowel Syndrome

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems. Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy. Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms.
Phase:
PHASE2
Details
Lead Sponsor:
Polyclinique de l'Europe
Treatments:
Amitriptyline
Mesotherapy
Pyrrolidonecarboxylic Acid
thiocolchicoside
Trimecaine